[203pb]vmt-α-net
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 15, 2021 (NCT05111509)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Drugs, Investigational · Phase 1/Phase 2
- Glioma · Phase 1
- Intestinal Neoplasms · Phase 1/Phase 2
- Kidney Neoplasms · Phase 1
- Neuroendocrine Tumors · Early Phase 1
- Paraganglioma · Phase 1/Phase 2
- Pheochromocytoma · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06427798 | Phase 1/Phase 2 (Phase 2) | Nov 17, 2024 | National Cancer Institute (NCI) |
| NCT06479811 | Phase 1 | Nov 17, 2024 | National Cancer Institute (NCI) |
| NCT05111509 | Early Phase 1 (Phase 1) | Dec 15, 2021 | National Cancer Institute (NCI), University of Iowa, Viewpoint Molecular Targeting |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 2 | 2 | 2021 |
| University of Iowa | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Viewpoint Molecular Targeting | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1